Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus FLUOCINONIDE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus FLUOCINONIDE ACETONIDE.
CAPEX vs FLUOCINONIDE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Fluocinonide acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply a thin film to affected area 1 to 3 times daily, depending on severity. Maximum: 2 weeks continuous use. Not for use on face, groin, or axillae. Dispense 15-60 g per application.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life is approximately 48-72 hours; prolonged in hepatic impairment due to reduced clearance; duration of action at skin sites persists up to 4-6 hours post-application.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <1% unchanged drug in urine; biliary/fecal excretion accounts for ~60% of metabolites.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid